Veridex, LLC announced that the U.S. Food and Drug Administration (FDA) has granted an expanded clearance for the CellSearch™ System to be used as an aid in the monitoring of metastatic prostate cancer (MPC) patients. The CellSearch™ System currently is cleared for monitoring metastatic breast and metastatic colorectal cancer patients. image

The CellSearch™ Circulating Tumor Cell (CTC) Test from Veridex is a simple blood test that captures and assesses CTCs to determine the prognosis of patients with metastatic breast cancer at any time. The test provides an objective, quantitative, real-time reading of tumor information so that oncologists can provide optimum care for their patients.

FDA Clears Cellsearch™ Circulating Tumor Cell Test For Monitoring Metastatic Prostate Cancer Patients


Post a Comment

Google Analytics Alternative